CSL Limited (FRA:CSJA)

Market Cap	48.24B
Revenue (ttm)	13.25B
Net Income (ttm)	2.56B
Shares Out	n/a
EPS (ttm)	5.25
PE Ratio	18.87
Forward PE	16.58
Dividend	1.20 (2.50%)
Ex-Dividend Date	Sep 10, 2025

Volume	n/a
Average Volume	n/a
Open	48.00
Previous Close	47.60
Day's Range	48.00 - 48.00
52-Week Range	47.40 - 85.50
Beta	n/a
RSI	47.97
Earnings Date	Feb 9, 2026

About CSL Limited

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1916
• Employees: 29,904
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CSJA

Financial Performance

In 2025, CSL Limited's revenue was $15.56 billion, an increase of 5.12% compared to the previous year's $14.80 billion. Earnings were $3.00 billion, an increase of 13.63%.

Financial numbers in USD